Latest Dana-Farber Cancer Institute Stories
Innovative international research consortium's first study opens SAN FRANCISCO, March 28, 2011 /PRNewswire-USNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI, voiced as "Alchemy") today announced the enrollment of the initial subjects into its inaugural clinical trial known as CASTLE, targeting 250 subjects over two years among academic and community medical centers in the United States.
The U.S. Food and Drug Administration today approved the use of ipilimumab for the treatment of previously treated metastatic melanoma.
BOSTON, March 24, 2011 /PRNewswire/ -- John Legere, CEO of Global Crossing, is nearing the finish line of his goal to raise $1 million for cancer research at Dana-Farber Cancer Institute.
Scientists reported on Wednesday that they have sequenced the entire genetic code of 38 multiple myeloma patients, and have uncovered the most likely genetic causes of the aggressive blood cancer.
Dana-Farber Cancer Institute scientists report they have shrunk or slowed the growth of notoriously resistant pancreatic tumors in mice, using a drug routinely prescribed for malaria and rheumatoid arthritis.
Using whole genome sequencing and multiple tumor samples, researchers uncover genes tied to prostate cancer growth.
Prostate tumors that carry a "signature" of four molecular markers have the potential to become dangerously metastatic if not treated aggressively.
By tweaking a single gene, scientists have mimicked in sedentary mice the heart-strengthening effects of two weeks of endurance training.
In early results, all participants responded to treatment with limited side effects ANN ARBOR, Mich., Dec.
A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients.
- A person who stands up for something, as contrasted to a bystander who remains inactive.
- One of the upright handlebars on a traditional Inuit sled.